Midatech Pharma plc logo
Midatech Pharma plc MTP

Annual report 2024
added 02-21-2026

report update icon

Midatech Pharma plc Total Assets 2011-2026 | MTP

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Midatech Pharma plc

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
14.8 M 10.5 M 5.52 M 12.9 M 9.82 M 30.9 M 20.4 M 49.2 M 56.7 M 64 M 50.6 M 5.17 M - -

All numbers in GBP currency

Indicator range from annual reports

Maximum Minimum Average
64 M 5.17 M 27.6 M

Quarterly Total Assets Midatech Pharma plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - 12.9 M - - - 9.82 M - - - 30.9 M - - - 20.4 M - - - 49.2 M - - - 56.7 M - - - 64 M - - - - - - - - - - - - - - - - - - -

All numbers in GBP currency

Indicator range from quarterly reporting

Maximum Minimum Average
64 M 9.82 M 34.9 M

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
11.6 M - 2.71 % $ 14 M usaUSA
I-Mab I-Mab
IMAB
6.33 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12 M - -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
778 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
66.7 M - - $ 26.5 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
1.36 B $ 3.71 2.77 % $ 1.11 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
15.2 M - -1.52 % $ 24.7 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
396 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
72 M - 4.01 % $ 150 M canadaCanada
Alector Alector
ALEC
293 M $ 2.07 -15.0 % $ 213 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
180 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.51 B - - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
47.1 M - 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
826 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
279 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
302 M - -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
34.8 M - 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
62.2 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
119 M - 4.14 % $ 49.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
287 M - - $ 2.17 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
35.1 M - 5.93 % $ 314 M canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
5.74 M - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
107 M - - $ 10.1 M usaUSA
Aravive Aravive
ARAV
62.2 M - -13.39 % $ 1.45 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
10.1 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
66.7 M - -39.0 % $ 4.57 M usaUSA
Athira Pharma Athira Pharma
ATHA
58.8 M - - $ 269 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
14.7 M - 17.91 % $ 11.1 M usaUSA
Altimmune Altimmune
ALT
139 M $ 4.22 -2.05 % $ 300 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
785 M - -6.81 % $ 3.04 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
1.16 B - - $ 867 M germanyGermany
Avenue Therapeutics Avenue Therapeutics
ATXI
2.67 M - -52.27 % $ 4.45 M usaUSA
Athersys Athersys
ATHX
60.2 M - 3.77 % $ 22.4 M usaUSA
Axcella Health Axcella Health
AXLA
18.9 M - -16.42 % $ 249 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
114 B - - $ 96.9 B britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
105 M - - $ 521 M usaUSA
Atreca Atreca
BCEL
155 M - -11.76 % $ 5.79 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
1.08 B $ 20.74 -1.05 % $ 2.62 B usaUSA
AVROBIO AVROBIO
AVRO
101 M - 1083.1 % $ 745 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
45.6 M $ 17.8 -2.52 % $ 855 M usaUSA
Agenus Agenus
AGEN
314 M $ 3.36 0.75 % $ 1.2 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.77 M - - $ 7.46 M israelIsrael
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
1.3 B $ 28.83 -4.63 % $ 1.67 B usaUSA
bluebird bio bluebird bio
BLUE
619 M - - $ 546 M usaUSA
Brickell Biotech Brickell Biotech
BBI
11.6 M - -5.38 % $ 6.06 M usaUSA